|
YALE COMPREHENSIVE CANCER CENTER
|
5P30CA016359-31
|
$1,889,710
|
$37,794
|
Lynch, Thomas
|
YALE UNIVERSITY
|
|
Vitamin D Analogs as Adjuvants in Chemotherapy
|
5R01CA044722-19
|
$205,937
|
$102,969
|
STUDZINSKI, GEORGE
|
UNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-34S1
|
$74,165
|
$742
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
3P30CA014089-34S2
|
$100,000
|
$1,000
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORT
|
5P30CA014089-34
|
$6,658,653
|
$66,587
|
JONES, PETER
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
3P50CA100632-07S1
|
$52,857
|
$26,957
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
University of Texas M.D. Anderson Cancer Center SPORE - Leukemia
|
5P50CA100632-07
|
$2,300,000
|
$1,173,000
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Translational Investigation of KRas & NF1 in Myeloid Leukemia
|
5R37CA072614-13
|
$310,254
|
$310,254
|
SHANNON, KEVIN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Towards a Mouse Model of Classical Hodgkin's Disease and PTLD
|
2R01CA098285-06A1
|
$487,828
|
$243,914
|
RAJEWSKY, KLAUS
|
IMMUNE DISEASE INSTITUTE, INC.
|
|
The role of tonic signal-input in stable gene profiles
|
5K01CA113367-04
|
$149,580
|
$29,916
|
ROOSE, JEROEN
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies
|
7K08CA134649-02
|
$127,170
|
$63,585
|
Li, Qing
|
UNIVERSITY OF MICHIGAN AT ANN ARBOR
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-16S1
|
$73,969
|
$2,959
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-16S2
|
$99,471
|
$3,979
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
3P30CA060553-16S3
|
$83,979
|
$3,359
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The Robert H. Lurie Comprehensive Cancer Center
|
5P30CA060553-16
|
$5,084,061
|
$203,362
|
Rosen, Steven
|
NORTHWESTERN UNIVERSITY
|
|
The RB Gene Family in Cancer Initiation
|
5R01CA114102-04
|
$278,016
|
$55,603
|
SAGE, JULIEN
|
STANFORD UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
3P30CA016058-34S1
|
$89,606
|
$2,688
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Ohio State University Comprehensive Cancer Center
|
5P30CA016058-34
|
$3,956,712
|
$118,701
|
CALIGIURI, MICHAEL
|
OHIO STATE UNIVERSITY
|
|
The Immunobiology of Marrow Allografts for Leukemia
|
5P01CA023766-31
|
$3,076,095
|
$615,219
|
O'REILLY, RICHARD
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Telomere Shortening and Stem Cell Maintenance
|
5K08CA118416-04
|
$140,010
|
$140,010
|
ARMANIOS, MARY
|
JOHNS HOPKINS UNIVERSITY
|
|
Targeting Wnt/Ca2+ Pathway components and Bcr-Abl for the treatment of CML
|
1K01CA133182-01A2
|
$110,419
|
$110,419
|
GREGORY, MARK
|
UNIVERSITY OF COLORADO DENVER
|
|
Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transpla
|
1R21CA137637-01A1
|
$338,800
|
$169,400
|
KONOPLEVA, MARINA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Study of the Roles of SDF1 and CXCR4 in Hematopoiesis
|
ZIA BC 010782
|
$327,420
|
$81,855
|
Tosato, Giovanna
|
CCR (NCI)
|
|
Studies of Proteins with Important Roles in Immunology and/or Cancer Biology
|
ZIA BC 010761
|
$487,255
|
$194,902
|
Lubkowski, Jacek
|
CCR (NCI)
|
|
Studies of BCR/ABL Leukemogenesis in Mice
|
5R01CA090576-10
|
$286,110
|
$286,110
|
Van Etten, Richard
|
TUFTS MEDICAL CENTER
|
|
Stanford University Cancer Center
|
3P30CA124435-03S1
|
$126,467
|
$2,529
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
Stanford University Cancer Center
|
5P30CA124435-03
|
$1,611,344
|
$32,227
|
MITCHELL, BEVERLY
|
STANFORD UNIVERSITY
|
|
Src Kinases in Ph+ Lymphoblastic Leukemia
|
7R01CA114199-05
|
$276,123
|
$276,123
|
LI, SHAOGUANG
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Signaling and targeting of FGFR1 fusions in 8p11 myeloproliferative syndrome
|
5R01CA120272-04
|
$263,700
|
$263,700
|
Chen, Jing
|
EMORY UNIVERSITY
|
|
Signal Transduction of Type I Interferons in Malignant Cells
|
5R01CA077816-12
|
$301,177
|
$301,177
|
PLATANIAS, LEONIDAS
|
NORTHWESTERN UNIVERSITY
|
|
Role of RNA Binding Proteins in BCR/ABL Leukemogenesis
|
5R01CA095512-06
|
$250,821
|
$250,821
|
Perrotti, Danilo
|
OHIO STATE UNIVERSITY
|
|
Role of Redox Dependent Signaling in Leukemia
|
5R01CA115811-03
|
$292,600
|
$292,600
|
CHANDRA, JOYA
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Role of MN1-TEL and MN1 in Leukemogenesis
|
5R01CA072996-13
|
$333,189
|
$333,189
|
GROSVELD, GERARD
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Role of Lipocalin 24p3 in Apoptosis and Leukemia
|
5R01CA115817-04
|
$252,065
|
$252,065
|
GREEN, MICHAEL
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Role of leukemia-associated protein MLF1 in apoptotic cell death
|
1F32CA138086-01A1
|
$50,054
|
$25,027
|
Pourpak, Alan
|
ST. JUDE CHILDREN'S RESEARCH HOSPITAL
|
|
Role of Dok-1 in oncogenic tyrosine kinase signaling
|
1R01CA135053-01A1
|
$348,600
|
$348,600
|
VAN AELST, LINDA
|
COLD SPRING HARBOR LABORATORY
|
|
Resistance of CML Stem Cells to Imatinib (Gleevec)
|
5R01CA095684-06
|
$320,589
|
$320,589
|
BHATIA, RAVI
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
Relapse after Allogeneci Hematopoietic Stem Cell Transplantation
|
ZIA BC 011239
|
$167,837
|
$151,053
|
Bishop, Michael
|
CCR (NCI)
|
|
Reactivating Apoptosis in Refractory Cancer by Selective Targeting of MCL-1
|
1F31CA144566-01
|
$32,232
|
$32,232
|
Stewart, Michelle
|
HARVARD UNIVERSITY (MEDICAL SCHOOL)
|
|
Rational Design and Clinical Development of Shepherdin: A Novel Anti-Cancer Agent
|
1R01CA118005-01A2
|
$340,386
|
$57,866
|
Altieri, Dario
|
UNIV OF MASSACHUSETTS MED SCH WORCESTER
|
|
Randomized study of combined epigenetic therapy
|
5R01CA121104-03
|
$292,600
|
$292,600
|
ISSA, JEAN-PIERRE
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
Radiation Protectors and Radiation Therapy Coupled Chemoprevention
|
1R01CA132998-01A2
|
$323,700
|
$323,700
|
GRDINA, DAVID
|
UNIVERSITY OF CHICAGO
|
|
Rac GTPases as Targets in Lymphomagenesis
|
5R01CA125658-03
|
$285,000
|
$285,000
|
ZHENG, YI
|
CHILDREN'S HOSPITAL MED CTR (CINCINNATI)
|
|
Program on Molecular and Cellular Mechanisms of Tumorigenesis
|
5P01CA016519-34
|
$1,922,663
|
$192,266
|
BOEKE, Jef
|
JOHNS HOPKINS UNIVERSITY
|
|
Predictors of Adult Leukemia
|
5R01CA107143-05
|
$491,742
|
$245,871
|
Ross, Julie
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
Phosphatase Targets of Lenalidomide in Myelodysplastic Syndrome
|
5R01CA131076-02
|
$436,029
|
$436,029
|
LIST, ALAN
|
H. LEE MOFFITT CANCER CTR & RES INST
|
|
Optimizing decitabine regimen + formulation for nonDNA damaging DNMT1 depletion
|
1R01CA138858-01
|
$329,202
|
$329,202
|
Saunthararajah, Yogen
|
CLEVELAND CLINIC LERNER COL/MED-CWRU
|
|
Opposing Roles for MEK/ERK in Differentiation & Leukemia
|
5R01CA108904-05
|
$249,963
|
$49,993
|
JOHNSON, DANIEL
|
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
|
|
Oncogene-Induced Evasion from Apoptosis
|
5R01CA105306-05
|
$318,352
|
$318,352
|
KHOSRAVI-FAR, ROYA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
NR4A Nuclear Receptor Function in Leukemia
|
3R01CA111411-04S1
|
$25,519
|
$25,519
|
CONNEELY, ORLA
|
BAYLOR COLLEGE OF MEDICINE
|
Total relevant funding to Chronic Myeloproliferative Disorders for this search: $32,529,168
|